Heparin USP update
July 20, 2015
The US Food and Drug
Administration has issued a
draft guidance document on
heparin, with the aim of reducing
medication errors and ensure the
safety of product containing the
blood thinning drug.
Comment is being sought on the
update, titled Heparin-Containing
Medical Devices and Combination
Products: Recommendations for
Labeling and Safety Testing, which
follows recent revisions to the
United States Pharmacopoeia
monograph for Heparin Sodium,
Heparin Lock Flush Solution and
Heparin Sodium Injection.
Proposed labelling changes follow
a “recurring trend of medication
errors related to misinterpretation
of the expression of concentration
on the labelling of injectable
products, resulting in serious
consequences to patients, including
death,” the FDA said - CLICK HERE.
The above article was sent to subscribers in Pharmacy Daily's issue from 20 Jul 15To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 20 Jul 15
